Drug intelligence / Profile preview

Realgar-Indigo naturalis formulation + anlotinib

Development stage: Unknown
Lead developer: Peking University People's Hospital
Modality: Small Molecules
Administration: Oral

Overview

This combination therapy consists of the Realgar-Indigo Naturalis Formulation (RIF) and anlotinib. RIF is a traditional Chinese medicine-derived formulation containing arsenic disulfide and indirubin, which has shown efficacy in hematological malignancies by inducing differentiation and apoptosis of malignant cells. Anlotinib is a potent, orally active multi-target tyrosine kinase inhibitor (TKI) that primarily targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptors (PDGFRα/β), and c-Kit. The combination is being investigated by Peking University People's Hospital for the treatment of platinum-resistant recurrent ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma, aiming to leverage the anti-angiogenic effects of anlotinib alongside the potential anti-tumor properties of RIF.

Other names: Realgar-Indigo Naturalis Formula Combined with AnlotinibRIF combined with anlotinib

Targets

PML-RARA (PML-retinoic acid receptor alpha fusion protein)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)

Beyond the preview

Go deeper on Realgar-Indigo naturalis formulation + anlotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Realgar-Indigo naturalis formulation + anlotinib.

Explore the full profile